Evidence map›Paper›PMID 26768437›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016

Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.

Leonard Chiu, Ronald Chow, Marko Popovic, Rudolph M Navari, Nathan M Shumway, Nicholas Chiu, Henry Lam, Milica Milakovic, Mark Pasetka, Sherlyn Vuong and 2 more

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07035821 (Olanzapine for the Treatment of Breakthrough Chemotherapy-Induced Vomiting in Children), which is not on this map. Cited by 46 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 11 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07035821 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Olanzapine for the Treatment of Breakthrough Chemotherapy-Induced Vomiting in Children: An Open-label, Randomized Phase 3 Trial

TypeinterventionalSponsorShanghai Children's Medical CenterRan2025 to 2026Enrolled100ConditionsBreakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients, Pediatric CancerArmsOlanzapine Tablets, Placebo
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 11 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Should palonosetron be a preferred 5-HTSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017
    Trial
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Leonard ChiuSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Ronald ChowSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Marko PopovicSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Rudolph M NavariIndiana University School of Medicine, South Bend, IN, USA.
Nathan M ShumwaySan Antonio Military Medical Center (SAMMC), San Antonio, TX, USA.
Nicholas ChiuSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Henry LamSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Milica MilakovicSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Mark PasetkaSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Sherlyn VuongSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Edward ChowSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. Edward.Chow@sunnybrook.ca.
Carlo DeAngelisSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Sunnybrook Health Science Centre · CAUniversity of Toronto · CAHealth Sciences Centre · CAIndiana University School of MedicineSan Antonio Military Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOlanzapine is a potent antipsychotic medication that inhibits a wide variety of receptors. It has been used in trials for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV). This study systematically investigates the efficacy of olanzapine in relation to other antiemetics in the prophylaxis and rescue of CINV.

methodsA literature search of Ovid MEDLINE, EMBASE, and CENTRAL was conducted to identify randomized controlled trials (RCTs) comparing olanzapine to other standard antiemetics for either prevention or rescue. The primary endpoints were the percentage of patients achieving no emesis or no nausea, in the acute, delayed, and overall phases.

resultsTen RCTs in the preventative setting and three RCTs in the breakthrough setting were identified. Subgroup analysis demonstrated a similar degree of benefit from a 5- and 10-mg dose of olanzapine for the no emesis endpoint in the overall phase. In the prophylaxis setting, olanzapine was statistically superior in five of six endpoints and clinically superior in four of six endpoints. In the breakthrough setting, olanzapine was statistically and clinically superior in the only endpoint analyzed: no emesis.

conclusionOlanzapine is more efficacious than other standard antiemetics for the rescue of CINV and its inclusion improves control in the prevention setting. Given the possible reduction in side effects, the use of a 5-mg dose of olanzapine should be considered. Future RCTs should compare the 5-mg versus the 10-mg dosages further and report on the efficacy and percentage of patients developing side effects. Further analyses should be done without the influence of corticosteroids.

Indexed as

AntiemeticsAntineoplastic AgentsBenzodiazepinesFemaleHumansInduction ChemotherapyNauseaOlanzapineVomitingAntiemeticsAntineoplastic AgentsBenzodiazepinesOlanzapineBreakthrough emesisChemotherapy-induced nausea and vomitingEfficacyOlanzapineProphylaxis

Identifiers

PMID26768437
OpenAlexW2236401105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.